OncoMatch/Clinical Trials/NCT07334431
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Is NCT07334431 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies fruquintinib＋trastuzumab + XELOX for gastric adenocarcinoma.
Treatment: fruquintinib＋trastuzumab + XELOX — This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) positive
HER2 positive
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: vegfr inhibitor
Cannot have received: chemotherapy
Cannot have received: immune checkpoint inhibitor
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelet ≥100×10^9 /L; Hemoglobin ≥90g/L
Kidney function
Serum creatinine (Cr) <1.5×ULN; Endogenous creatinine clearance ≥50ml/min
Liver function
Total bilirubin < 1.5 ULN; ALT and/or AST < 1.5 ULN
Cardiac function
LVEF (Left ventricular Ejection Fraction) <50% or >50% excluded; NYHA >Level 2 excluded; severe/unstable angina, MI, CABG within 6 months excluded; ventricular arrhythmias requiring treatment excluded
The functions of vital organs met the following requirements... (see above for details); Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) <50% or >50% excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify